Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C21H40N8O5 |
| Molecular Weight | 484.5929 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 3 / 3 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCN([C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(=O)CN
InChI
InChIKey=LPKPGXJXCZNDJO-JYJNAYRXSA-N
InChI=1S/C21H40N8O5/c1-2-28(17(30)13-23)16(8-3-4-10-22)19(32)29-12-6-9-15(29)18(31)27-14(20(33)34)7-5-11-26-21(24)25/h14-16H,2-13,22-23H2,1H3,(H,27,31)(H,33,34)(H4,24,25,26)/t14-,15-,16-/m0/s1
| Molecular Formula | C21H40N8O5 |
| Molecular Weight | 484.5929 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 3 / 3 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Icrocaptide, also known as ITF 1697, a chemically modified LYS-Pro tetrapeptide that was studied to reduce reperfusion injury. The ability of icrocaptide to inhibit the early functions of activated endothelial cells could be used as pharmacological tool in model of pathologies of a variety of microvascular disorders. In addition, tetrapeptide was involved in phase II clinical trials for patients undergoing percutaneous transluminal coronary angioplasty with or without coronary stenting. As a result, a trend toward reperfusion improvement was seen.
Originator
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| ITF1697, a stable Lys-Pro-containing peptide, inhibits weibel-palade body exocytosis induced by ischemia/reperfusion and pressure elevation. | 2007-07-16 |
|
| The effect of ITF-1697 on reperfusion in patients undergoing primary angioplasty. Safety and efficacy of a novel tetrapeptide, ITF-1697. | 2004-03 |
|
| Use of type I and type IV hypersensitivity responses to define the immunopharmacological profile of drugs. | 1997-03 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/15033251
Intravenous infusion of four dosages of ITF-1697 (0.1, 0.5, 1.0 or 2.0 microg/kg/min) or placebo
Route of Administration:
Intravenous
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:31:16 GMT 2025
by
admin
on
Mon Mar 31 18:31:16 GMT 2025
|
| Record UNII |
8Z05BX342T
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Systematic Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C308
Created by
admin on Mon Mar 31 18:31:16 GMT 2025 , Edited by admin on Mon Mar 31 18:31:16 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
8249
Created by
admin on Mon Mar 31 18:31:16 GMT 2025 , Edited by admin on Mon Mar 31 18:31:16 GMT 2025
|
PRIMARY | |||
|
CHEMBL2107753
Created by
admin on Mon Mar 31 18:31:16 GMT 2025 , Edited by admin on Mon Mar 31 18:31:16 GMT 2025
|
PRIMARY | |||
|
216295
Created by
admin on Mon Mar 31 18:31:16 GMT 2025 , Edited by admin on Mon Mar 31 18:31:16 GMT 2025
|
PRIMARY | |||
|
300000025263
Created by
admin on Mon Mar 31 18:31:16 GMT 2025 , Edited by admin on Mon Mar 31 18:31:16 GMT 2025
|
PRIMARY | |||
|
DTXSID00937645
Created by
admin on Mon Mar 31 18:31:16 GMT 2025 , Edited by admin on Mon Mar 31 18:31:16 GMT 2025
|
PRIMARY | |||
|
C90810
Created by
admin on Mon Mar 31 18:31:16 GMT 2025 , Edited by admin on Mon Mar 31 18:31:16 GMT 2025
|
PRIMARY | |||
|
169543-49-1
Created by
admin on Mon Mar 31 18:31:16 GMT 2025 , Edited by admin on Mon Mar 31 18:31:16 GMT 2025
|
PRIMARY | |||
|
8Z05BX342T
Created by
admin on Mon Mar 31 18:31:16 GMT 2025 , Edited by admin on Mon Mar 31 18:31:16 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|